Eli Lilly and Company (LLY)vsOramed Pharmaceuticals Inc (ORMP)
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
ORMP
Oramed Pharmaceuticals Inc
$3.81
+4.38%
HEALTHCARE · Cap: $149.38M
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 35.0% profit margin vs 0.0%. ORMP trades at a lower P/E of 1.4x. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
ORMP
Hold45
out of 100
Grade: D
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 58 in profit
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Earnings expanding 40.9% YoY
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Revenue declined 100.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : ORMP
The strongest argument for ORMP centers on P/E Ratio, Price/Book, Return on Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : ORMP
The primary concerns for ORMP are Market Cap, Profit Margin, Operating Margin.
Key Dynamics to Monitor
LLY profiles as a growth stock while ORMP is a value play — different risk/reward profiles.
ORMP carries more volatility with a beta of 1.24 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 45/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Oramed Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for the administration of polypeptides. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?